Bronchitis - Pipeline Review, H2 2012

Global Markets Direct, August 2012, Pages: 73

Bronchitis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Bronchitis - Pipeline Review, H2 2012', provides an overview of the Bronchitis therapeutic pipeline. This report provides information on the therapeutic development for Bronchitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchitis. 'Bronchitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bronchitis.
- A review of the Bronchitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bronchitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bronchitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Bronchitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Bronchitis Therapeutic Products under Development, Key Players in Bronchitis Therapeutics, Bronchitis Pipeline Overview, Bronchitis Pipeline, Bronchitis Pipeline Assessment

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Bronchitis Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Bronchitis 9
Bronchitis Therapeutics under Development by Companies 11
Bronchitis Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Bronchitis Therapeutics – Products under Development by Companies 18
Bronchitis Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Bronchitis Therapeutics Development 20
PARI Pharma GmbH 20
Yuhan Corporation 21
Mucosis B.V. 22
APT Pharmaceuticals, Inc. 23
aRigen Pharmaceuticals, Inc. 24
iNova Pharmaceuticals (Australia) Pty Limited 25
Pacific Therapeutics Ltd. 26
Bronchitis – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
Pulminiq - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Erdosteine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
PTL-202 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Nebulized Hypertonic Saline - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Montelukast - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Dexamethasone - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Ventolin + Dexamethasone - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 41
Bortezomib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Symbicort. - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Cyclosporine Inhalation Solution - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Symbicort - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
L-CsA - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Mycophenolate Sodium + Cyclosporin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 51
Salbutamol + Hypertonic Saline - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Mesenchymal Stromal Cells - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Fluticasone Propionate + Azithromycin + Montelukast Sodium - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 55
YHD-001 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Azithromycin - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
SynGEM - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Bronchitis Therapeutics – Drug Profile Updates 60
Bronchitis Therapeutics – Discontinued Products 62
Bronchitis Therapeutics - Dormant Products 63
Bronchitis – Product Development Milestones 65
Featured News & Press Releases 65
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA 65
Feb 11, 2010: PARI Pharma Initiates Enrollment In Phase IIb Study Of Liposomal Cyclosporine Against Bronchiolitis Obliterans 65
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans 66
Oct 01, 2008: Pharmaxis Files First Marketing Application For Bronchitol In Australia 67
Aug 20, 2008: 12 Month Phase 3 Trial Finds Bronchitol Safe In Bronchiectasis 67
Jul 05, 2007: Pharmaxis Completes Phase III Bronchiectasis Trial 68
Apr 11, 2007: Pharmaxis Begins Phase III Cystic Fibrosis Trial 69
Feb 06, 2006: Pharmaxis Commences Operations In Europe 69
Jul 20, 2005: US FDA Grants Bronchitol Orphan Drug Status For Treatment Of Cystic Fibrosis 70
Sep 28, 2004: Abbott Announces FDA Approval of New Omnicef (Cefdinir) Oral Suspension Dosage for Pediatric Use. 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables
Number of Products Under Development for Bronchitis, H2 2012 9
Products under Development for Bronchitis – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
PARI Pharma GmbH, H2 2012 20
Yuhan Corporation, H2 2012 21
Mucosis B.V., H2 2012 22
APT Pharmaceuticals, Inc., H2 2012 23
aRigen Pharmaceuticals, Inc., H2 2012 24
iNova Pharmaceuticals (Australia) Pty Limited, H2 2012 25
Pacific Therapeutics Ltd., H2 2012 26
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 32
Bronchitis Therapeutics – Drug Profile Updates 60
Bronchitis Therapeutics – Discontinued Products 62
Bronchitis Therapeutics – Dormant Products 63
Bronchitis Therapeutics – Dormant Products (Contd..1) 64

List of Figures
Number of Products under Development for Bronchitis, H2 2012 9
Products under Development for Bronchitis – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Route of Administration, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Molecule Type, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 32

Customers who bought this item also bought

• Drug Addiction – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013